Showing 821 - 840 results of 927 for search '"Leukemia"', query time: 0.07s Refine Results
  1. 821

    Inherited Thrombocytopenia Related Genes: GPS2 Mediates the Interplay Between ANKRD26 and ETV6 by Valeria Capaci, Melania Eva Zanchetta, Giorgia Fontana, Daniele Ammeti, Roberta Bottega, Michela Faleschini, Anna Savoia

    Published 2024-12-01
    “…Mutations in 5′UTR of ANKRD26, leading to ANKRD26-RT, disrupt this regulation, resulting in the persistent expression of ANKRD26, which leads to impaired platelet biogenesis and an increased risk of leukemia. Although ANKRD26 and ETV6 exhibit inverse expression during megakaryopoiesis, ETV6 does not regulate the ANKRD26 expression. …”
    Get full text
    Article
  2. 822

    Increased local DNA methylation disorder in AMLs with DNMT3A-destabilizing variants and its clinical implication by Dohoon Lee, Bonil Koo, Seokhyeon Kim, Jamin Byun, Junshik Hong, Dong-Yeop Shin, Choong-Hyun Sun, Jaesung Kim, Ji-Joon Song, Siddhartha Jaiswal, Sung-Soo Yoon, Sun Kim, Youngil Koh

    Published 2025-01-01
    “…Abstract The mechanistic link between the complex mutational landscape of de novo methyltransferase DNMT3A and the pathology of acute myeloid leukemia (AML) has not been clearly elucidated so far. …”
    Get full text
    Article
  3. 823

    CD4+CD25highCD127low Regulatory T Cells in Peripheral Blood Are Not an Independent Factor for Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation by Jolanta B. Perz, Selma Gürel, Stefan O. Schonland, Ute Hegenbart, Anthony D. Ho, Peter Dreger

    Published 2012-01-01
    “…The therapeutic efficacy of allogeneic hemopoietic stem cell transplantation (HSCT) largely relies on the graft-versus-leukemia (GVL) effect. Uncontrolled graft-versus-host disease (GVHD) is a feared complication of HSCT. …”
    Get full text
    Article
  4. 824

    Dasatinib-Induced Pulmonary Arterial Hypertension Treated with Upfront Combination Therapy by Makoto Nishimori, Tomoyuki Honjo, Kenji Kaihotsu, Naohiko Sone, Sachiko Yoshikawa, Junichi Imanishi, Kazuhiko Nakayama, Noriaki Emoto, Masanori Iwahashi

    Published 2018-01-01
    “…Pulmonary arterial hypertension (PAH) is a rare complication of dasatinib that was approved as a first-line therapy for chronic myelocytic leukemia (CML). A 24-year-old man presenting dyspnea at rest and leg edema was admitted to our hospital. …”
    Get full text
    Article
  5. 825

    A Novel Attention-Guided Enhanced U-Net With Hybrid Edge-Preserving Structural Loss for Low-Dose CT Image Denoising by Muhammad Zubair, Helmi Md Rais, Talal Alazemi

    Published 2025-01-01
    “…Computed Tomography (CT) scan, pivotal for medical diagnostics, involves exposure to electromagnetic radiation, potentially elevating the risk of leukemia and cancer. Low-dose CT (LDCT) imaging has emerged to mitigate these risks, extensively reducing radiation exposure by up to 86%. …”
    Get full text
    Article
  6. 826

    Design and In Vitro Biological Evaluation of a Novel Organotin(IV) Complex with 1-(4-Carboxyphenyl)-3-ethyl-3-methylpyrrolidine-2,5-dione by Nebojša Đ. Pantelić, Bojana B. Zmejkovski, Željko Žižak, Nebojša R. Banjac, Bojan Đ. Božić, Tatjana P. Stanojković, Goran N. Kaluđerović

    Published 2019-01-01
    “…In vitro anticancer activity of ligand precursor and synthesized organotin(IV) compound was determined against tumor cell lines: human adenocarcinoma (HeLa), human myelogenous leukemia (K562), and human breast cancer (MDA-MB-453), using microculture tetrazolium test (MTT) assay. …”
    Get full text
    Article
  7. 827

    Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database by Tingting Jiang, Yanping Li, Ni Zhang, Lanlan Gan, Hui Su, Guiyuan Xiang, Yuanlin Wu, Yao Liu

    Published 2025-01-01
    “…Background: Gilteritinib and midostaurin are FLT3 inhibitors that have made significant progress in the treatment of acute myeloid leukemia. However, their real-world safety profile in a large sample population is incomplete. …”
    Get full text
    Article
  8. 828

    Empagliflozin Reverses Oxidized LDL-Induced RECK Suppression, Cardiotrophin-1 Expression, MMP Activation, and Human Aortic Smooth Muscle Cell Proliferation and Migration by Bysani Chandrasekar, Srinivas Mummidi, Vincent G. DeMarco, Yusuke Higashi

    Published 2023-01-01
    “…OxLDL-induced cardiotrophin (CT)-1 expression and CT-1 stimulated SMC proliferation and migration in part via leukemia inhibitory factor receptor (LIFR) and glycoprotein 130 (gp130). …”
    Get full text
    Article
  9. 829

    Cytotoxic and Antioxidant Effects of Antimalarial Herbal Mixtures by Isaac Dadzie, Shaibu Adams Avorgbedo, Regina Appiah-Opong, Obed Cudjoe

    Published 2020-01-01
    “…The dried samples were tested on human acute T-cell leukemia (Jurkat) and breast adenocarcinoma (MCF-7) cell lines. …”
    Get full text
    Article
  10. 830

    The Characterization of L-Asparaginase with Low L-Glutaminase Activity Produced by the Marine <i>Pseudomonas</i> sp. Strain GH-W2b by Woon-Jong Yu, Ha Young Lee, Yong Min Kwon, Seung Seob Bae, Grace Choi, Hyun-Ju Hwang, Dawoon Chung

    Published 2024-12-01
    “…L-asparaginase (ASNase) hydrolyzes L-asparagine to L-aspartic acid and ammonia and has been used as an antitumor agent for the treatment of acute lymphoblastic leukemia. ASNase has also been used to mitigate the suspected carcinogenic effects of acrylamide in foods. …”
    Get full text
    Article
  11. 831

    Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab by Ziping Li, Fujing Zhang, Xianghong Jin, Junling Zhuang

    Published 2025-01-01
    “…Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that these DEPs were enriched in cytokine-cytokine receptor interaction and JAK-STAT signaling pathways. Leukemia inhibitory factor (LIF) is the most correlated with other DEPs and thus may play a key role in both enriched pathways, and the level of LIF protein was highest in the BiTe group. …”
    Get full text
    Article
  12. 832

    Automated workflow for the cell cycle analysis of (non-)adherent cells using a machine learning approach by Kourosh Hayatigolkhatmi, Chiara Soriani, Emanuel Soda, Elena Ceccacci, Oualid El Menna, Sebastiano Peri, Ivan Negrelli, Giacomo Bertolini, Gian Martino Franchi, Roberta Carbone, Saverio Minucci, Simona Rodighiero

    Published 2024-11-01
    “…This method was validated in acute myeloid leukemia cell lines NB4 and Kasumi-1, which have unique cell cycle characteristics, and we tested the impact of cell cycle-modulating drugs on NB4 cells. …”
    Get full text
    Article
  13. 833

    MicroRNA-155 modulates methotrexate-induced spatial memory impairment by disruption of the blood-brain barrier integrity by Yu-Chieh Chen, Li-Tung Huang, Hong-Ren Yu, Jiunn-Ming Sheen

    Published 2025-03-01
    “…Main methods: We use young rat model mimicking children leukemia treatment protocol, focusing on the systemic MTX effect on the central nervous system by intraperitoneal (IP) MTX injection. …”
    Get full text
    Article
  14. 834

    Solid lipid nanoparticles for increased oral bioavailability of acalabrutinib in chronic lymphocytic leukaemia by Swagata Sinha, Punna Rao Ravi, Makarand Somvanshi, S. R. Rashmi

    Published 2024-12-01
    “…Abstract Acalabrutinib (ACP) is a first-line treatment for chronic lymphocytic leukemia but suffers from poor and variable oral bioavailability due to its pH-dependent solubility, CYP3A4 metabolism, and P-gp efflux. …”
    Get full text
    Article
  15. 835

    Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course by Angela McLigeyo, Jamilla Rajab, Mohammed Ezzi, Peter Oyiro, Yatich Bett, Andrew Odhiambo, Matilda Ong’ondi, Sitna Mwanzi, Mercy Gatua, NAOthieno- Abinya

    Published 2020-01-01
    “…Imatinib mesylate is the gold standard for the treatment of all phases of Philadelphia-positive chronic myeloid leukemia. Patients on imatinib treatment may develop cytopenia due to drug toxicity. …”
    Get full text
    Article
  16. 836

    Comparative Approach to Define Increased Regulatory T Cells in Different Cancer Subtypes by Combined Assessment of CD127 and FOXP3 by Marc Beyer, Sabine Classen, Elmar Endl, Matthias Kochanek, Martin R. Weihrauch, Svenja Debey-Pascher, Percy A. Knolle, Joachim L. Schultze

    Published 2011-01-01
    “…In recent years an increase of functional CD4+CD25+ regulatory T cells (Treg cells) has been established for patients with solid tumors, acute leukemias, and lymphomas. We have reported an expanded pool of CD4+CD25high Treg cells in patients with chronic lymphatic leukemia (CLL), multiple myeloma (MM) as well as its premalignant precursor monoclonal gammopathy of undetermined significance (MGUS). …”
    Get full text
    Article
  17. 837

    Successful desensitization of donor-specific antibodies in a single cord blood transplant recipient by Mégane Tanguay, Sandra Cohen, Isabelle Ménard, Marie-Christine Meunier, Jean-Sébastien Delisle, Jean Roy, Olivier Veilleux, Imran Ahmad

    Published 2025-12-01
    “…Existing literature on HLA desensitization has primarily focused on haploidentical transplants, and there is a lack of experience regarding the optimal strategy in UCB transplantation.Methods: We report our successful desensitization strategy in a 42-year-old woman with acute lymphoblastic leukemia receiving a single UCB unit. The only suitable donor option for this patient, who had no relatives and uncommon HLA haplotypes, was a UCB graft against which the patient had DQ7 DSAs.Results: DSA levels were reduced before transplantation through a combination of plasma exchange, intravenous immunoglobulins, and rituximab with close monitoring of DSA mean fluorescent intensity levels. …”
    Get full text
    Article
  18. 838

    Refractory human cytomegalovirus infection without evidence of genetic resistance in the UL-54 and UL-97 genes in a pediatric hematopoietic stem cell transplant recipient: a case r... by Alejandra Pando-Caciano, Ketty Adid Escudero-Ramirez, Jackeline Carol Rodríguez-Torres, Holger Maita-Malpartida, Holger Maita-Malpartida

    Published 2024-02-01
    “…Here, we present a case of an 8 years-old patient diagnosed with acute myeloid leukemia. Eight months post-diagnosis, the patient underwent TCR-αβ+/CD19+-depleted haploidentical HSCT. …”
    Get full text
    Article
  19. 839

    Canadian Clinical Practice Guidelines for Invasive Candidiasis in Adults by Eric J Bow, Gerald Evans, Jeff Fuller, Michel Laverdière, Coleman Rotstein, Robert Rennie, Stephen D Shafran, Don Sheppard, Sylvie Carle, Peter Phillips, Donald C Vinh

    Published 2010-01-01
    “…Over the past few years, a new and broader understanding of the epidemiology and pathogenesis of C/IC has emerged and has been coupled with the availability of new antifungal agents and defined strategies for targeting groups at risk including, but not limited to, acute leukemia patients, hematopoietic stem cell transplants and solid organ transplants, and critical care unit patients. …”
    Get full text
    Article
  20. 840

    Agro-morphological characterization and assessment of metabolic profiling and anticancer activities in various tribulus (Tribulus terrestris L.) populations by Yasamin Dabaghkar, Ghasem Eghlima, Hossein Behboudi, Mohammadtaghi Ebrahimi, Mansour Ghorbanpour

    Published 2025-01-01
    “…Abstract Tribulus terrestris L. from the family of Zygophyllaceae, which is rich in saponin compounds, especially diosgenin, has various biological properties, such as anti-inflammation, anti-Alzheimer, anti-obesity, anti-diabetes, anti-leukemia, and anti-cancer activities, due to these compounds. …”
    Get full text
    Article